HCWBNasdaqPharmaceutical PreparationsFiscal year ends December 31
HCW Biologics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$1.23−0.01 (-0.81%)
Close on Oct 19, 2026
- Market cap
- $1.63M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$22.71 (−94.86%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsSplit
HCW Biologics Inc. grew revenue 700.2% to $6.66M over the twelve months to Jun 30, 2026. Free cash flow was -$13.39M.
Revenue
$6.66M
+700.2% vs. a year earlier
Operating income
-$7.68M
TTM Q2 2026
Free cash flow
-$13.39M
FY2025
EPS, diluted
-$28.41
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $1.63M
- P/E ratio
- –
- Price to sales
- 0.25
- Price to book
- 0.22
- Dividend yield
- –
- Free cash flow yield
- -819.86%
Fundamentals
- Revenue
- $6.66M
- Net income
- -$5.58M
- EPS, diluted
- -$28.41
- Free cash flow
- -$13.39M
- Book value per share
- $5.59
- Diluted shares
- 1M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
$6.66M+700.2% YoY
Gross profit
$6.45M+3770.2% YoY
Operating income
-$7.68M
Net income
-$5.58M
EPS, diluted
-$28.41
Free cash flow
–
Reported periodTrailing twelve months